Table 3.
Univariate correlations with irisin and mRNA expression of skeletal muscle FNDC5
Baseline | After 3 months Treatment with rhGH | |||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Serum Irisin | Skeletal Muscle FNDC5 mRNA | Serum Irisin | Skeletal Muscle FNDC5 mRNA | |||||
| ||||||||
ρ | P Value | ρ | P Value | ρ | P Value | ρ | P Value | |
Body Composition Parameters | ||||||||
| ||||||||
BMI (kg/m2) | 0.38 | .17 | −0.15 | .68 | 0.21 | .46 | 0.09 | .80 |
Iliac Waist (cm) | 0.30 | .28 | −0.24 | .51 | 0.11 | .70 | 0.26 | .47 |
Total fat mass (kg) | 0.39 | .16 | −0.16 | .65 | 0.09 | .76 | −0.02 | .96 |
Total lean mass (kg) | −0.14 | .62 | 0.04 | .91 | 0.05 | .85 | −0.09 | .80 |
| ||||||||
Metabolic Parameters | ||||||||
| ||||||||
Peak stimulated GH on GHRH-arginine (μg/L) | −0.20 | .49 | −0.45 | .19 | -- | -- | -- | -- |
IGF-I (μg/L) | −0.38 | .17 | 0.08 | .83 | 0.20 | .47 | −0.22 | .53 |
| ||||||||
Energy Parameters | ||||||||
| ||||||||
REE (kcal/day) | 0.30 | .28 | 0.32 | .37 | 0.10 | .73 | 0.16 | .65 |
REE/total lean mass (kcal/day*kg) | 0.30 | .27 | 0.26 | .47 | 0.24 | .40 | 0.31 | .38 |
RQ | −0.18 | .52 | −0.49 | .15 | −0.15 | .58 | −0.19 | .60 |
VO2 (L/min) | 0.31 | .27 | 0.37 | .29 | 0.19 | .50 | 0.19 | .60 |
VCO2 (L/min) | 0.19 | .50 | 0.16 | .65 | 0.06 | .84 | 0.03 | .93 |
| ||||||||
Mitochondrial Function | ||||||||
| ||||||||
τPC | −0.10 | .74 | −0.28 | .43 | −0.02 | .95 | 0.19 | .60 |
ViPCr (mM/min) | 0.48 | .08 | 0.79 | .006 | −0.02 | .96 | 0.22 | .53 |
PCr (mM) | ||||||||
Rest | 0.48 | .08 | 0.22 | .53 | 0.27 | .36 | −0.20 | .58 |
Beginning of recovery | 0.48 | .08 | 0.13 | .73 | 0.05 | .88 | −0.30 | .40 |
End of recovery | 0.38 | .18 | 0.04 | .91 | 0.24 | .41 | 0.02 | .96 |
ADP (uM) | ||||||||
Rest | −0.64 | .01 | −0.35 | .33 | 0.03 | .93 | 0.13 | .71 |
Beginning of recovery | −0.75 | .002 | −0.56 | .09 | 0.31 | .29 | −0.05 | .88 |
End of recovery | −0.58 | .03 | −0.25 | .49 | −0.09 | .76 | −0.01 | .99 |
| ||||||||
mRNA Expression | ||||||||
| ||||||||
IGF-I | 0.63 | .05 | 0.81 | .005 | 0.05 | .88 | 0.66 | .04 |
PGC-1α | 0.44 | .21 | 0.68 | .03 | 0.19 | .60 | 0.39 | .26 |
PPARγ | 0.73 | .02 | 0.85 | .002 | 0.01 | .99 | 0.10 | .78 |
PPARα | 0.37 | .29 | 0.62 | .05 | 0.03 | .93 | 0.25 | .49 |
NRF1 | 0.54 | .11 | 0.66 | .04 | −0.07 | .85 | 0.58 | .08 |
TFAM | 0.48 | .16 | 0.79 | .007 | 0.03 | .93 | 0.38 | .28 |
Relationships were assessed by Spearman’s Correlation Coefficient.
Gene expression values are normalized to GAPDH, results are expressed as ratios in arbitrary units
Abbreviations: rhGH, recombinant human growth hormone; FNDC5, fibronectin type III domain-containing protein 5; BMI, body mass index; GHRH, growth hormone releasing hormone; REE, resting energy expenditure; RQ, respiratory quotient, VO2, maximal oxygen consumption; VCO2, carbon dioxide production; PCr, phosphocreatine; τ, recovery time constant; Vi, initial rate; ADP, adenosine diphosphate; PGC-1α, peroxisome proliferator-activated receptor γ coactivator 1α; PPAR, peroxisome proliferator-activated receptor; NRF1, nuclear respiratory factor; TFAM, mitochondrial transfer factor A